Skip to main content
amavitaRESEARCH

For Patients

Find a Clinical Trial That Fits You

Explore active studies at our Miami facility. Each trial includes detailed eligibility, study sponsor, and contact information.

Larkin Hospital Referral Partnership

Patients are referred from and supported by our hospital partner network for seamless, continuity-focused care during participation.

HypertensionHFrEFHFpEFACSPADIron-Deficiency HF
Advanced Cardiovascular of Miami catheterization lab
Affiliated Surgery Center

Advanced cardiovascular care in a comfortable, same-day setting

The only ambulatory surgery center of its kind in South Florida.

All trial-related procedures are performed at our affiliated state-of-the-art surgical center in Miami — the only one of its kind in South Florida — so you receive advanced cardiovascular care in a comfortable, same-day outpatient setting.

9408 SW 87th Ave., Suite 303, Miami, FL 33176

Showing 7 of 7 trials

Phase 3Hypertension● Currently Recruiting

ZENITH — Zilebesiran (RNAi)

Treatment-Resistant Hypertension

Protocol: Alnylam ALN-AGT01-008

Phase 3 evaluation of zilebesiran, an investigational RNAi therapeutic targeting AGT, for adults with treatment-resistant hypertension and elevated cardiovascular risk.

Sponsor: Alnylam Pharmaceuticals · PI: Dr. William W. O'Neill, MD, FACC (Senior PI)

Key Eligibility

  • Adults 18+ with treatment-resistant hypertension
  • Currently on ≥3 antihypertensive medications
  • Elevated cardiovascular risk profile
Apply for this trial
Phase 3ACS● Currently Recruiting

Librexia ACS

Acute Coronary Syndrome

Protocol: Pfizer C4921003

Pivotal Phase 3 study evaluating a novel antithrombotic strategy in patients following an acute coronary syndrome event.

Sponsor: Pfizer

Key Eligibility

  • Adults with recent ACS event
  • Clinically stable for randomization
  • On standard-of-care therapy
Apply for this trial
Phase 2Heart FailureRecruiting

JK07 — Heart Failure

Heart Failure (across EF ranges)

Protocol: JK07201

Novel heart failure therapy under investigation across the spectrum of ejection fraction, including HFrEF, HFmrEF, and HFpEF.

Sponsor: JK07 Bio

Key Eligibility

  • Adults 18–85 with chronic heart failure
  • NYHA Class II–III symptoms
  • On stable guideline-directed medical therapy
Apply for this trial
Phase 3Heart FailureRecruiting

IV Ferric Derisomaltose

Iron-Deficient Heart Failure

Phase 3 evaluation of intravenous ferric derisomaltose in patients with heart failure and iron deficiency to improve outcomes and quality of life.

Sponsor: Pharmacosmos

Key Eligibility

  • Adults with HFrEF or HFpEF
  • Confirmed iron deficiency (TSAT <20% or ferritin criteria)
  • Stable on guideline-directed therapy
Apply for this trial
Phase 1Heart FailureEnrolling Soon

Phase 1 HFpEF — VS-041

HFpEF

First-in-human evaluation of VS-041, a novel mechanism targeting cardiac structural remodeling in heart failure with preserved ejection fraction.

Sponsor: VASA Therapeutics

Key Eligibility

  • Adults 40–80 with NYHA Class II–III HFpEF
  • LVEF ≥ 50%
  • Elevated NT-proBNP
Apply for this trial
Phase 2Heart FailureRecruiting

HFpEF — PF-07328948

HFpEF (Metabolic Therapy)

Metabolic-pathway therapy under investigation for symptomatic improvement in heart failure with preserved ejection fraction.

Sponsor: Pfizer

Key Eligibility

  • Adults with confirmed HFpEF
  • BMI ≥ 27
  • Stable cardiovascular medications ≥ 30 days
Apply for this trial
Phase 3VascularRecruiting

Golazo® GREAT — Peripheral Atherectomy

Peripheral Artery Disease

Pivotal evaluation of an advanced peripheral atherectomy system for treatment of calcified lower-extremity arterial disease.

Sponsor: Cardiovascular Systems Inc.

Key Eligibility

  • Adults 18+ with symptomatic PAD
  • Rutherford Class 2–4
  • Suitable target lesion on imaging
Apply for this trial

FAQ

Frequently Asked Questions

Common questions from patients exploring clinical trial participation at Amavita Research.